Conquering breast cancer is not an easy feat. Once it's beaten, there's always a chance it could come back. Now doctors are working on a new way to help breast cancer survivors win the fight once and for all.
Kellie Trombitas is a fighter. It took 33 rounds of radiation for her to knock-out breast cancer over ten tough months.
Kellie Trombitas, Breast cancer survivor, explains how tough the 33 rounds of radiation was on her, "Chemo takes a lot out of you. You're sick, I mean, it just makes you sick."
Now, she's excited to be cancer free. Kellie still has concerns.
Trombitas explains her fears that she still has, "In the back of your mind you're always thinking, is it going to come back?"
So she's taking part in this clinical trial, to test E-75. The vaccine is to help protect breast cancer survivors from recurrence. E-75 is a part of the HER2 Neu protein. It helps stimulate T-cells to attack cancer cells.
In trials, women injected with the vaccine saw a 50 percent reduction in recurrence. The drug Herceptin can do the same but in a different way. Only 20 percent of breast cancer survivors, those with high levels of HER2, can take Herceptin. E-75 developer George Peoples says three times as many survivors could benefit from his vaccine. It targets women like Kellie, who have lower levels of HER2.
George E. Peoples MD, FACS, Surgical Oncology, SAMMC, explains how the vaccine works, "It allows us to use the vaccine for patients who are otherwise not eligible to receive Herceptin."
As for Kellie she's still getting stronger.
Trombitas explains how she is feeling now, "It's just a good feeling."
She is now fighting to keep cancer from making a comeback.
Doctor Peoples says one day the vaccine could be used to fight lung, prostate and ovarian cancers that also express the HER2 protein. Recruiting for the final round of trials for E-75 is underway right now.
700 to 1,000 participants in dozens of sites across the country are needed.
TOPIC: KNOCKOUT! VACCINE FIGHTS BREAST CANCER RECURRENCE
REPORT: MB #3437
BACKGROUND: According to U.S. cancer statistics, 1 in 8 women will develop invasive breast cancer over the course of her lifetime. In 2011, an estimated 230,480 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 57,650 new cases of non-invasive breast cancer. Breast cancer is the second most common diagnosed cancer among American women. (Source: www.breastcancer.org).
RISK FACTORS: A woman's risk of breast cancer increases by nearly half if she has an immediate family member who has been diagnosed with breast cancer. About 15% of women who get breast cancer have a family member diagnosed with it. About 5-10% of breast cancers can be linked to gene mutations inherited from one's mother or father. Mutations of the BRCA1 and BRCA2 genes are the most common. Women with these mutations have up to an 80% risk of developing breast cancer during their lifetime, and they are more likely to be diagnosed at a younger age (pre-menopause). (Source: www.breastcancer.org).
TREATMENT AND RECURRENCE: Breast cancer treatments can be local or systemic. Treatments include; surgery, radiation therapy, chemotherapy, hormone therapy, and biological therapy such as Herceptin. Herceptin works by using the body's own immune system to destroy cancer cells. Herceptin targets breast cancer cells that have high levels of a protein called HER2. Amplification or over-expression of the ERBB2 gene occurs in approximately 30% of breast cancers. It is strongly associated with increased disease recurrence and a worse prognosis. HER2 proteins have been shown to form clusters in cell membranes that may play a role in tumorigenesis. Recurrent breast cancer is breast cancer that comes back after initial treatment. Although treatment is aimed at eliminating all cancer cells, a few may survive. These undetected cancer cells multiply, becoming recurrent breast cancer. It may occur months or years after your initial treatment. (Source: webmd.com, mayoclinic).
NEW TREATMENT - NeuVax E-75 is a vaccine given as supplementary therapy to prevent disease recurrence. NeuVax consists of the E-75 peptide derived from human epidermal growth factor receptor 2 (HER2) combined with the immune adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly definitive approach to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase 2 trial, which achieved its primary endpoint of disease-free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. A Phase 3 trial is expected to begin in the first half of 2012. (Source: www.globenewswire.com).
Mallet finger due to loss of central extensor tendon to the distal phalanx
FOR MORE INFORMATION, PLEASE CONTACT:
Jen D. Rodriguez
BAMC Public Affairs Media Relations Coordinator
If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Andrew McIntosh at email@example.com.